Avoiding calcineurin inhibitors in the early post-operative course in high-risk liver transplant recipients: The role of extracorporeal photopheresis

Journal of Clinical Apheresis

Volumn 22, Issue 4, 2007, Pages 187-194

  Urbani, Lucio ^a   Mazzoni, Alessandro ^a   De Simone, Paolo ^a   Catalano, Gabriele ^a   Coletti, Laura ^a   Petruccelli, Stefanie ^a   Biancofiore, Gianni ^a   Bindi, Lucia ^a   Scatena, Fabrizio ^a   Filipponi, Franco ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Calcineurin inhibitors; Immunosuppression; Liver transplantation; Nephrotoxicity; Neurotoxicity; Photopheresis

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; GLUCONATE CALCIUM; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HYPOCALCEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; MORTALITY; NEPHROTOXICITY; NEUROTOXICITY; POSTOPERATIVE CARE; PUVA; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

CALCINEURIN; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, ACUTE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PHOTOPHERESIS; POSTOPERATIVE COMPLICATIONS;

EID: 34548262685     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20111     Document Type: Article

References (25)

1. Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, Emre S, Fishbein TM, Guy SR, Schwartz ME, Miller CM. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 2000; 69:781-789.
2. Jain A, Reyes J, Kashyap R, Rohal S, Abu-Elmagd K, Starzl T, Fung J. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1,000 patients. Ann Surg 1999;230:441-448.
3. Neal DA, Tom BD, Luan J, Wareham NJ, Gimson AE, Delriviere LD, Byrne CD, Alexander GJ. Is there disparity between risk and incidence of cardiovascular disease after liver transplant? Transplantation 2004;77:93-99.
4. Munoz SJ, Elgenaidi H. Cardiovascular risk factors after liver transplantation. Liver Transplant 2005;11(Suppl 2):52-56.
5. Marchetti P. New-onset diabetes after liver transplantation: from pathogenesis to management. Liver Transpl 2005;11:612-620.
6. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002;35:1179-1185.
7. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. NEJM 2003;349:931-940.
8. Ponticelli C, Campise MR. Neurological complications in kidney transplant recipients. J Nephrol 2005;18:521-528.
9. Guarino M, Stracciari A, Pazzaglia P, Sterzi R, Santilli I, Donato F, D'Alessandro R. Neurological complications of liver transplantation. J Neurol 1996;243:137-142.
10. Furukawa H, Todo S. Evolution of immunosuppression in liver transplantation: contribution of Cyclosporine. Transplant Proc 2004; 36(Suppl 2):S274-S284.
11. Beckebaum S, Cicinnati VR, Broelsch CE. Future directions in immunosuppression. Transplant Proc 2004;36(Suppl 2):S574-S576.
12. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000;13:313.
13. Emre S, Gondolesi G, Polat K, Ben-Haim M, Artis T, Fishbein TM, Sheiner PA, Kim-Schluger L, Schwartz ME, Miller CM. Use of daclizumab as initial immunosuppression in liver transplant recipients wit impaired renal function. Liver Transpl 2001; 7:220-225.
14. Hirose R, Roberts JP, Quan D, Osorio RW, Freise C, Ascher NL, Stock PG Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000;69:307-311.
15. Kasner SE, Sheth KN, Wu GF, Messe SR, Wolf RL. Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients. Neurology 2005;65:337-338.
16. Sanchez EQ, Martin AP, Ikegami T, Uemura T, Narasimhan G, Goldstein RM, Levy MF, Chinnakotla S, Dawson S 3rd, Randall HB, Saracino G, Klintmaim GB. Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. Transplant Proc 2005;37:4416-4423.
17. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Invest Drugs 2002;11:1845-1857.
18. Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transplant 2004;10:728-733.
19. Heffron TG, Smallwood GA, Pillen T, Davis L, Martinez E, Romero R, Stieber AC. Liver transplant induction trial of daclizumab to spare calcineurin inhibition. Transplant Proc 2002;34: 1514-1515.
20. Sellers MT, McGuire BM, Haustein SV Bynon JS, Hunt SL, Echoff DE. Two-dose daclizumab induction therapy in 209 liver transplants: a single-center analysis. Transplantation 2004;78: 1212-1217.
21. McKenna KE, Whittaker S, Rhodes LE, Taylor P, Lloyd J, Ibbotson S, Russell-Jones R;British Photodermatology Group; UK Skin Lymphoma Group. Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. Br J Dermatol 2006;154:7-20.
22. Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U, Donato M, Champlin R. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? Biol Blood Marrow Transplant 2006;12(Suppl 2):37-40.
23. Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. NEJM 1998;339: 1744-1751.
24. Urbani L, Mazzoni A, Catalano G, De Simone P, Vanacore R, Pardi C, Bortoli M, Biancofiore G, Campani D, Perrone V, Mosca F, Scatena F, Filipponi F. The use of extracorporeal photopheresis for allograft rejection in liver transplant recipients. Transplant Proc 2004;36:3068-3070.
25. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.